Hepato-Gastroenterologie HK s.r.o. — Clinical Trial Site

48 Registered trials

14 Currently recruiting

Organisation

Hepato-Gastroenterologie HK s.r.o.

Location

Hradec Kralove, Czechia

Identifier

ORG-100042224

Address

Trida Edvarda Benese 1549/34, 500 12, Czechia

Departments

CZ10003
CZ10003: Hepto - gastroenterologie
Gastroenterologie
Gastroenterology
Gastroenterology Department
Gastroenterology outpatient department
hepato-gastro enterologie
Hepato-Gastroenterologie
Hepato-Gastroenterologie HK s.r.o.
Hepato-gastroenterologie HK, s.r.o.
Hepatology, Gastroenterology
Hradecka poliklinika lll
N/A
NA
Poliklinika III
site 001_Hepato Gastroenterologie
Třída Edvarda Beneše 1549/34, Nový Hradec Králové 500 12 Hradec Králové, Czech Republic

Clinical trials at this site (48)

Search interface

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended

2023-506769-67-00 Moderate to Severely Active Ulcerative Colitis 4 2024-09-04
Dose-finding study of SAR443122 in adult participants with ulcerative colitis Ended

2022-500290-14-01 Colitis ulcerative 4 2023-05-11
A study to investigate changes in symptoms and esophageal histology with tezepelumab compared with placebo in patients aged 12 to 80 years o… Ended

2023-504277-20-00 Eosinophilic esophagitis (EoE) is a rare, chronic infla 5 2023-01-30
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2) Ended

2022-502841-91-00 Crohn’s Disease 5 2020-08-12
ELEVATE UC OLE: An Open-Label Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Ended

2024-515156-21-00 Ulcerative Colitis 5 2020-01-09
A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended

2023-506994-36-00 Ulcerative Colitis 5 2018-10-11
LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended

2023-507657-15-00 Ulcerative Colitis 5 2018-09-13
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504736-18-00 Moderately to Severely Active Crohn's Disease 10 2018-07-26
A Placebo controlled Maintenance and Long-term Extension Study of the Efficacy and Safety of Risankizumab in Participants with Crohn's Disea… Ended

2023-506399-28-00 Crohn's Disease 5 2017-11-08
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Comple… Ended

2023-504951-29-00 Chron's Disease 5 2017-07-27
Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis. Ended

2023-505699-31-00 Ulcerative Colitis 5 2017-01-02
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic … Ended

2023-507771-22-01 Primary Biliary Cholangitis (PBC) 5 2025-04-03
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended

2023-506655-19-00 Ulcerative Colitis (UC) 4 2024-05-16
Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504673-20-00 Ulcerative Colitis 4 2023-12-06
A Study to Investigate Bowel Urgency in Adults with Moderately to Severely Active Ulcerative Colitis Treated with Mirikizumab Ended

2022-502393-16-00 Moderately to Severely Active Ulcerative Colitis 5 2023-09-06
Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended

2023-506046-24-00 Ulcerative Colitis (UC) 4 2023-07-03
ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended

2022-500535-36-01 Moderately to severely active ulcerative colitis 5 2023-06-12
Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis Ended

2023-506004-93-00 Ulcerative Colitis (UC) 4 2022-03-01
VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Ended

2023-509233-39-00 Moderately to Severely Active Ulcerative Colitis 4 2022-01-20
A clinical study of tulisokibart for the treatment of ulcerative colitis (MK-7240-005) Ended

2023-509741-12-00 Ulcerative Colitis 4 2021-09-23
A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenan… Ended

2024-513569-38-00 Crohn's Disease 10 2021-07-09
A study to learn about the effects and safety of obeticholic acid in combination with bezafibrate in participants with primary biliary chola… Ended

2024-513762-18-00 Primary Biliary Cholangitis (PBC) 4 2019-09-20
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended

2024-511553-22-00 Moderately to Severely Active Crohn's Disease 5 2018-10-05
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease Ended

2023-510426-33-00 Moderately to Severely Active Crohn's Disease 5 2018-09-27